Abstract: Two had SDRMs to nucleoside reverse-transcriptase inhibitors (D67G and L210W), three had SDRMs to nonnucleoside reverse transcriptase inhibitors (G190A, G190S, and K101E), and one had SDRMs to protease inhibitors (N88D).
Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India.
PMID: 21568760
2011
AIDS research and human retroviruses
Abstract: As per the 2009 WHO list of mutations for surveillance of transmitted HIVDR, only one nonnucleoside reverse transcriptase inhibitor (NNRTI) mutation was detected at K101E from all specimens tested, suggesting a low prevalence (<5%) of resistance to NNRTIs and no mutations were detected at other sites, suggesting a low prevalence (<5%) of resistance to nucleoside reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI) drug classes as well.
Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
PMID: 21592625
2011
Enfermedades infecciosas y microbiologia clinica
Abstract: ETR-RAMs were defined as V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S, and M230L, and were analyzed according to the weighted mutation score to predict susceptibility (Vingerhoets 2008).
Abstract: Most frequent ETR-RAMs after failure with EFV: G190A (28.1%), K101E (14.9%), L100I (10.5%); and with NVP: Y181C (41.7%), G190A (30.6%) and A98G (13.9%).
High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo.
PMID: 21663632
2011
Journal of the International AIDS Society
Result: V106A/M, K101E and Y188C/L were noted in four, three and two patients, respectively.
Table: K101E
Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents.
PMID: 21745701
2011
European journal of medicinal chemistry
Abstract: Compound 11 exhibited extremely potent anti-HIV activity against NL4-3 (wild-type), NL4-3 (K101E), and RTMDR viral strains, with EC(50) values of 0.086, 0.15, and 0.11 nM, respectively.
Conclusion: The hydrochloride salt 11 retained its sub-nanomolar activity against NRTI-resistant (K101E) and multi-drug-resistant HIV strains (RTMDR).
Method: Anti-HIV replication assay against NL4-3 (K101E) and RTMDR strains in TZM-bl cell lines.
Method: NL4-3 (K101E) or RTMDR at a multiplicity of infection (MOI) of 0.001 was used to infect TZM-bl cells.
Result: In our screening, 11 exhibited extremely potent anti-HIV activity against NL4-3 (wild-type), NL4-3 (K101E), and RTMDR, with EC50 values of 0.086, 0.15, and 0.11 nM, respectively.
Result: In the
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Abstract: Reverse transcriptase (RT) genotypes with the NNRTI resistance mutations K101E+G190S are highly resistant to efavirenz (EFV) and can develop during failure of EFV-containing regimens in patients.
Abstract: Additionally, we showed that another NNRTI, nevirapine (NVP), stimulated K101E+G190S virus replication during the early steps of infection similar to EFV, but that the newest NNRTI, etravirine (ETR), did not.
Abstract: We also showed that EFV stimulates K101E+Y188L and K101E+V106I virus, but not PMID: 21953939
2011
ChemMedChem
Abstract: Mutations detected for nevirapine virological failure with a prevalence greater than 10% in the used patient set were: K103N, Y181C, G190A, and K101E.
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Result: Longer duration of failure was also significantly associated with higher risk of M184V (PP[OR>1] = 94%) and NNRTI mutations G190A (PP[OR>1] = 95%), K101E (PP[OR>1] = 94%) and A98G (PP[OR>1] = 99%).
Result: The K103N (P<0.001) and P225H (P<0.001) mutations were each significantly more common and Y181C/I (P = 0.001), G190A (P = 0.002) and K101Q/E (P = 0.003) were each significantly less common among subjects failing efavirenz-based treatment as compared to those failing nevirapine-based treatment.
Result: When adjusted for the effects of failure duration, viral load and NRTI b
Prevalence and patterns of HIV transmitted drug resistance in Guatemala.
PMID: 22358416
2011
Revista panamericana de salud publica
Abstract: Major NNRTI mutations such as K101E, K103N, and E138K showed higher frequencies than expected in ART-naive populations.
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
PMID: 19933797
2010
Antimicrobial agents and chemotherapy
Abstract: NNRTI RAMs emerging in HIV-1 under selective pressure from TMC278 included combinations of V90I, L100I, K101E, V106A/I, V108I, E138G/K/Q/R, V179F/I, Y181C/I, V189I, G190E, H221Y, F227C, and M230I/L.
HIV mutation literature information.
PMID: 
2011
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT